New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
06:32 EDTALXNAlexion announces EC grants orphan drug designation for Soliris
Alexion announced that the European Commission has granted an orphan drug designation to Soliris, a first-in-class terminal complement inhibitor, for the prevention of delayed graft function after solid organ transplantation. DGF is an early and serious complication of organ transplantation that is characterized by the failure of a transplanted organ to function normally immediately following transplantation. In patients undergoing kidney transplantation, patients who develop DGF require dialysis in order to survive.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
06:35 EDTALXNAlexion submits NDA in Japan for treatment of hypophosphatasia
Subscribe for More Information
October 9, 2014
10:41 EDTALXNHigh option volume stocks
Subscribe for More Information
06:36 EDTALXNAlexion appoints new chairman and creates Lead Independent Director position
Alexion has appointed Leonard Bell, M.D. as Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as CEO. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby has been a Director of Alexion since September 1999. Both of these appointments follow the passing of Max Link, Ph.D., who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the company’s inception in 1992.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use